Dyne Therapeutics, Inc. announced the successful completion of its public offering of 27,878,788 shares of common stock at a price of $8.25 per share, generating approximately $230 million in gross ...
- Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne’s first planned commercial launch in early 2027 - - Registrational Expansion Cohort of DELIVER ...
Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne ...
Dyne Therapeutics, Inc. (DYN) is advancing the use of its FORCE platform to target skeletal muscle disorders. This would be with the use of modern oligonucleotide technology drugs like DYNE-101 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results